Other · developed by Pulmatrix
PUR118 is a drug studied in cystic fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01543191 | Phase 1 | Cystic Fibrosis | Completed | PULM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cystic Fibrosis
Updated Nov 15, 2026. Something wrong or missing? Report it on the PULM page.
See PULM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PULM catalysts and pipeline →